Tearsheet

Surgery Partners (SGRY)


Market Price (12/26/2025): $15.63 | Market Cap: $2.0 Bil
Sector: Health Care | Industry: Health Care Facilities

Surgery Partners (SGRY)


Market Price (12/26/2025): $15.63
Market Cap: $2.0 Bil
Sector: Health Care
Industry: Health Care Facilities

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.


0 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31%
Weak multi-year price returns
2Y Excs Rtn is -99%, 3Y Excs Rtn is -120%
Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 184%
1 Attractive yield
FCF Yield is 9.8%
Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%
2 Low stock price volatility
Vol 12M is 48%
  Key risks
SGRY key risks include [1] its significant debt and high leverage, Show more.
3 Megatrend and thematic drivers
Megatrends include Healthcare Delivery Transformation. Themes include Ambulatory Surgical Care, Outpatient Care Shift, and Value-Based Healthcare Delivery.
  
0 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31%
1 Attractive yield
FCF Yield is 9.8%
2 Low stock price volatility
Vol 12M is 48%
3 Megatrend and thematic drivers
Megatrends include Healthcare Delivery Transformation. Themes include Ambulatory Surgical Care, Outpatient Care Shift, and Value-Based Healthcare Delivery.
4 Weak multi-year price returns
2Y Excs Rtn is -99%, 3Y Excs Rtn is -120%
5 Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
6 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 184%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%
8 Key risks
SGRY key risks include [1] its significant debt and high leverage, Show more.

Valuation, Metrics & Events

SGRY Stock


Why The Stock Moved


Qualitative Assessment

AI Analysis | Feedback

Here are five key points explaining the approximate -31.1% movement in Surgery Partners (SGRY) stock from August 31, 2025, to December 26, 2025:

1. Surgery Partners reported a significant miss on its Third Quarter 2025 earnings, with an Earnings Per Share (EPS) of $0.13, falling short of analyst estimates of $0.19 on November 10, 2025. The company's quarterly revenue of $821.50 million also came in below analyst expectations of $823.55 million.

2. Following the disappointing Q3 2025 results, Surgery Partners revised its full-year guidance downward for both revenue and adjusted EBITDA. This adjustment reflected delayed capital deployment, the timing of ASC sale proceeds, and a more cautious outlook on fourth-quarter payer mix and volume, particularly due to softer-than-expected commercial volumes.

Show more

Stock Movement Drivers

Fundamental Drivers

The -27.6% change in SGRY stock from 9/25/2025 to 12/25/2025 was primarily driven by a -28.6% change in the company's P/S Multiple.
925202512252025Change
Stock Price ($)21.5915.63-27.61%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)3237.003288.101.58%
P/S Multiple0.850.60-28.60%
Shares Outstanding (Mil)126.98127.21-0.18%
Cumulative Contribution-27.61%

LTM = Last Twelve Months as of date shown

Market Drivers

9/25/2025 to 12/25/2025
ReturnCorrelation
SGRY-27.6% 
Market (SPY)4.9%-1.7%
Sector (XLV)16.2%-5.0%

Fundamental Drivers

The -28.0% change in SGRY stock from 6/26/2025 to 12/25/2025 was primarily driven by a -30.2% change in the company's P/S Multiple.
626202512252025Change
Stock Price ($)21.7015.63-27.97%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)3172.903288.103.63%
P/S Multiple0.870.60-30.16%
Shares Outstanding (Mil)126.60127.21-0.48%
Cumulative Contribution-27.97%

LTM = Last Twelve Months as of date shown

Market Drivers

6/26/2025 to 12/25/2025
ReturnCorrelation
SGRY-28.0% 
Market (SPY)13.1%9.3%
Sector (XLV)16.6%8.8%

Fundamental Drivers

The -25.6% change in SGRY stock from 12/25/2024 to 12/25/2025 was primarily driven by a -31.9% change in the company's P/S Multiple.
1225202412252025Change
Stock Price ($)21.0115.63-25.61%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)2985.303288.1010.14%
P/S Multiple0.890.60-31.90%
Shares Outstanding (Mil)126.17127.21-0.82%
Cumulative Contribution-25.61%

LTM = Last Twelve Months as of date shown

Market Drivers

12/25/2024 to 12/25/2025
ReturnCorrelation
SGRY-25.6% 
Market (SPY)15.8%27.9%
Sector (XLV)13.3%26.3%

Fundamental Drivers

The -41.4% change in SGRY stock from 12/26/2022 to 12/25/2025 was primarily driven by a -43.1% change in the company's Shares Outstanding (Mil).
1226202212252025Change
Stock Price ($)26.6715.63-41.39%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)2442.403288.1034.63%
P/S Multiple0.970.60-37.72%
Shares Outstanding (Mil)88.91127.21-43.08%
Cumulative Contribution-52.27%

LTM = Last Twelve Months as of date shown

Market Drivers

12/26/2023 to 12/25/2025
ReturnCorrelation
SGRY-51.6% 
Market (SPY)48.3%28.3%
Sector (XLV)18.5%30.2%

Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
SGRY Return85%84%-48%15%-34%-26%-0%
Peers Return9%51%-7%20%24%27%185%
S&P 500 Return16%27%-19%24%23%18%115%

Monthly Win Rates [3]
SGRY Win Rate67%67%42%50%42%33% 
Peers Win Rate52%67%48%54%58%60% 
S&P 500 Win Rate58%75%42%67%75%73% 

Max Drawdowns [4]
SGRY Max Drawdown-70%-5%-58%-20%-39%-29% 
Peers Max Drawdown-53%-7%-33%-10%-5%-20% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: THC, HCA, UHS, UNH.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)

How Low Can It Go

Unique KeyEventSGRYS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-66.7%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven200.7%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-76.1%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven317.7%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven143 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-76.7%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven328.4%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven398 days120 days

Compare to ACHC, AMTU, MCTA, PARK, HCA

In The Past

Surgery Partners's stock fell -66.7% during the 2022 Inflation Shock from a high on 6/25/2021. A -66.7% loss requires a 200.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Surgery Partners (SGRY)

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

AI Analysis | Feedback

Here are 1-3 brief analogies for Surgery Partners (SGRY):

  • HCA Healthcare for surgical facilities.

  • Like a specialized version of a major hospital operator such as Tenet Healthcare, but exclusively for surgeries and short-stay procedures.

  • Universal Health Services (UHS), but focused solely on surgical hospitals and ambulatory surgical centers.

AI Analysis | Feedback

  • Surgical Care Services: Provides a comprehensive range of surgical procedures across various medical specialties in its network of surgical hospitals and ambulatory surgery centers.
  • Ancillary Healthcare Services: Offers complementary medical services such as diagnostic imaging, urgent care, and physician practice management that support and integrate with its surgical facilities.

AI Analysis | Feedback

Surgery Partners (SGRY) primarily sells its healthcare services to individuals.

The company serves individuals falling into the following categories, largely distinguished by their primary method of payment:

  • Patients with Commercial Insurance: These are individuals covered by private health insurance plans (e.g., UnitedHealthcare, Anthem, Aetna, Cigna, Humana). Surgery Partners bills these insurance companies for the majority of the cost of services provided, with the patients responsible for co-payments, deductibles, and co-insurance.
  • Patients with Government Insurance: This category includes individuals covered by government-sponsored healthcare programs such as Medicare (primarily for the elderly and some disabled individuals) and Medicaid (for low-income individuals and families). Surgery Partners bills these government programs for services rendered.
  • Self-Pay Patients: These are individuals who either do not have health insurance or choose not to use it for specific services. They are directly responsible for paying the full cost of the healthcare services they receive from Surgery Partners' facilities.

AI Analysis | Feedback

null

AI Analysis | Feedback

Eric Evans, Chief Executive Officer
Eric Evans has served as Chief Executive Officer and Director of Surgery Partners, Inc. since January 2020, having previously been Executive Vice President and Chief Operating Officer since April 2019. Prior to joining Surgery Partners, Mr. Evans spent nearly 20 years in various operating and strategic roles in healthcare services, including serving as President of Hospital Operations for Tenet Healthcare, where he was responsible for 68 acute care hospitals and 161 hospital-affiliated facilities. He also held positions as CEO of Tenet's Texas Region and market leadership roles, as well as Chief of Staff to the CEO. Surgery Partners is backed by private equity firm Bain Capital.

David T. Doherty, Executive Vice President and Chief Financial Officer
David T. Doherty was appointed Executive Vice President and Chief Financial Officer of Surgery Partners, Inc. in February 2022. He joined Surgery Partners in April 2018 and served as Senior Vice President of Corporate Finance and Controller since August 2018. Before his tenure at Surgery Partners, Mr. Doherty spent 15 years at Aetna Inc., where he held various senior financial management roles, including leadership positions in internal audit, planning, risk management, and serving as assistant controller. He earned his CPA while working at Arthur Andersen, LLP.

Jennifer B. Baldock, Executive Vice President, Chief Administrative Officer and General Counsel
Jennifer B. Baldock holds the title of Executive Vice President, Chief Administrative Officer and General Counsel at Surgery Partners. She is also listed as Executive Vice President and Chief Administrative & Development Officer.

Marissa Brittenham, Executive Vice President & Chief Strategy Officer
Marissa Brittenham was appointed Chief Strategy Officer of Surgery Partners, Inc. in January 2022. Her prior experience includes leading Growth at Cityblock Health and Medicaid Partnerships at Evolent Health, and she previously served as an Associate Partner at McKinsey & Company.

Jon Fredrickson, Senior Vice President & Chief Information Officer
Jon Fredrickson has served as Senior Vice President & Chief Information Officer for Surgery Partners since April 2025. He has held various leadership and CISO positions within Surgery Partners and across the healthcare sector, spanning both provider and payer markets.

AI Analysis | Feedback

Here are the key risks to Surgery Partners (SGRY):
  1. Dependence on Third-Party Payors and Regulatory Changes: Surgery Partners' business model is heavily reliant on contracts with third-party payors, including Medicare, Medicaid, and private insurance organizations. This exposes the company to substantial risks from changes in healthcare policies, reimbursement rates, and contract negotiations, which can significantly impact its financial stability and profitability. The healthcare industry is also subject to stringent and complex regulations, and any changes in laws or compliance requirements can pose significant threats, potentially leading to revenue and profitability impacts, as well as penalties for non-compliance.
  2. High Debt Levels and Leverage: The company carries significant debt, which can limit its financial flexibility, constrain its ability to invest in growth opportunities, and make it more vulnerable to rising interest rates or adverse economic changes. For instance, Surgery Partners has a notable net-debt-to-EBITDA ratio, which lenders may view unfavorably and could necessitate dilutive equity offerings if additional capital is needed.
  3. Operational Challenges and Profitability Concerns: Despite experiencing revenue growth, Surgery Partners has reported net losses in various periods, indicating ongoing operational challenges. Factors contributing to these losses include increased operating expenses, such as salaries, benefits, and supplies, as well as higher interest expenses. The company's ability to achieve sustained profitability and effectively manage its costs remains a significant concern.

AI Analysis | Feedback

The following are clear emerging threats for Surgery Partners (SGRY):

  • Accelerated Vertical Integration and Consolidation by Large Payers and Providers: Major healthcare payers, particularly UnitedHealth Group's Optum division, are aggressively expanding their provider networks through acquisitions of physician groups, ambulatory surgery centers, and specialty clinics. This vertical integration allows these entities to steer patients to their owned facilities, negotiate more favorable internal rates, and potentially limit independent providers like SGRY from participating in preferred networks or receiving competitive reimbursement rates. This trend represents a significant shift in market power towards integrated systems, potentially reducing the volume and negotiating leverage of independent surgical facility operators.
  • Persistent Healthcare Labor Shortages and Wage Inflation: The healthcare industry continues to face acute shortages of critical personnel, including registered nurses, surgical technicians, anesthesiologists, and certain surgical specialists. This widespread labor crunch, exacerbated by factors like an aging workforce and post-pandemic burnout, drives significant wage inflation and increases recruitment and retention costs. For SGRY, which relies on efficient staffing and high utilization of its facilities, these pressures directly compress operating margins and can limit the capacity for growth or even force temporary operational reductions due to insufficient staff.

AI Analysis | Feedback

Surgery Partners (SGRY) operates primarily within the United States, focusing on surgical facilities and related ancillary services. The main addressable markets for their services in the U.S. include Ambulatory Surgery Centers and Physician Services.

Ambulatory Surgery Centers (ASCs)

The addressable market for Ambulatory Surgery Centers (ASCs) in the U.S. was estimated to be between approximately USD 40.41 billion and USD 51.2 billion in 2024. This market is projected to grow significantly, with estimates suggesting it could reach around USD 60.8 billion by 2030, USD 62.03 billion by 2032, or even USD 103.4 billion by 2033/2034. This growth is driven by factors such as increased demand for outpatient procedures, cost-effectiveness, and technological advancements.

Physician Services

Surgery Partners also offers physician services, including multi-specialty physician practices and anesthesia services. The U.S. physician groups market, which encompasses these services, was estimated at USD 349.49 billion in 2024. This market is projected to expand to approximately USD 542.99 billion by 2030.

Surgical Hospitals

While Surgery Partners operates surgical hospitals, a specific addressable market size solely for "surgical hospitals" within the U.S. is not clearly delineated in the provided market research. The broader U.S. hospital services market, however, was valued at USD 2.48 trillion in 2024 and is projected to reach approximately USD 4.02 trillion by 2034. The global surgical hospital market was estimated at USD 19 billion in 2025.

AI Analysis | Feedback

Here are the expected drivers of future revenue growth for Surgery Partners (SGRY) over the next 2-3 years:
  1. Growth in Surgical Case Volume, particularly in Higher-Acuity Specialties: Surgery Partners anticipates continued revenue expansion driven by an increase in surgical case volumes, with a specific focus on the accelerated migration of higher-acuity procedures, such as orthopedics and joint replacements, from traditional hospital settings to outpatient facilities. The company has reported robust growth in total joint surgeries within its ambulatory surgery centers (ASCs).
  2. Strategic Acquisitions and Partnerships: A key component of Surgery Partners' growth strategy involves strategic acquisitions and partnerships. The company consistently deploys capital for acquiring new surgical facilities and physician practices, aiming to expand its operational footprint and diversify its service offerings.
  3. DeNovo Facility Development: Surgery Partners is investing in the development of new "DeNovo" facilities. These new facilities are primarily concentrated in higher-acuity specialties, with a significant emphasis on orthopedics, and are expected to contribute to long-term revenue growth.
  4. Rate Improvement and Revenue per Case: The company's revenue growth is also supported by improvements in revenue per case. While surgical case volume is expected to be a larger driver, strategic rate adjustments contribute to overall top-line expansion.
  5. Operational Efficiencies and Margin Expansion: Though not a direct revenue driver, Surgery Partners' focus on operational efficiencies and margin expansion through cost management and procurement initiatives is crucial. Improved profitability and cash flow generation provide increased financial flexibility to self-fund growth initiatives, indirectly supporting sustainable revenue growth.

AI Analysis | Feedback

Share Repurchases

  • Surgery Partners had $46 million remaining under its $50 million share repurchase program as of December 31, 2024.
  • The company made share repurchases totaling approximately $9.56 million between Q1 2020 and Q2 2021.

Share Issuance

  • In 2022, Surgery Partners reported equity offering proceeds, net of related costs, of $857.7 million.
  • The number of common shares outstanding increased from 126,607,086 as of February 19, 2024, to 127,613,091 as of February 24, 2025, and further to 129,341,779 as of November 3, 2025.

Outbound Investments

  • In 2024, the company acquired a controlling interest in eight surgical facilities and several physician practices for a total cash consideration of $378.8 million.
  • Approximately $225 million was deployed for acquisitions in 2023, alongside the opening of eight new facilities.
  • Year-to-date in 2025 (as of Q3), $71 million in capital was deployed for acquisitions. The company also divested interests in three ambulatory surgery centers (ASCs) for $50 million in the first half of 2025.

Capital Expenditures

  • Maintenance capital expenditures for the third quarter of 2025 were $10 million.
  • Surgery Partners deployed approximately $325 million in capital across 12 transactions in 2021, which included increasing its installed base of robotics in its ambulatory surgery centers (ASCs).
  • The company's goal for 2022 was to deploy at least $200 million in capital.

Better Bets than Surgery Partners (SGRY)

Trade Ideas

Select ideas related to SGRY. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
21.1%21.1%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-6.7%-6.7%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
16.7%16.7%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
2.3%2.3%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
11.8%11.8%-5.1%
SGRY_10312024_Dip_Buyer_FCFYield10312024SGRYSurgery PartnersDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
-22.1%-23.9%-33.0%
SGRY_2292024_Dip_Buyer_FCFYield02292024SGRYSurgery PartnersDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
1.3%-22.4%-36.8%

Recent Active Movers

More From Trefis

Peer Comparisons for Surgery Partners

Peers to compare with:

Financials

SGRYTHCHCAUHSUNHMedian
NameSurgery .Tenet He.HCA Heal.Universa.UnitedHe. 
Mkt Price15.63197.77474.06227.08327.58227.08
Mkt Cap2.017.4113.414.3296.817.4
Rev LTM3,28820,84672,69816,993435,15920,846
Op Inc LTM4993,34711,0781,94926,3573,347
FCF LTM1941,5027,29295017,3721,502
FCF 3Y Avg1681,6785,70477318,9681,678
CFO LTM2822,47811,9351,94820,9582,478
CFO 3Y Avg2572,55010,4511,64122,4432,550

Growth & Margins

SGRYTHCHCAUHSUNHMedian
NameSurgery .Tenet He.HCA Heal.Universa.UnitedHe. 
Rev Chg LTM10.1%-0.6%6.4%10.2%10.5%10.1%
Rev Chg 3Y Avg10.4%3.1%6.6%8.7%11.4%8.7%
Rev Chg Q6.6%3.2%6.4%13.4%12.2%6.6%
QoQ Delta Rev Chg LTM1.6%0.8%1.6%3.2%2.9%1.6%
Op Mgn LTM15.2%16.1%15.2%11.5%6.1%15.2%
Op Mgn 3Y Avg14.7%13.8%15.0%9.8%7.7%13.8%
QoQ Delta Op Mgn LTM0.8%0.4%0.1%0.5%-1.2%0.4%
CFO/Rev LTM8.6%11.9%16.4%11.5%4.8%11.5%
CFO/Rev 3Y Avg8.6%12.3%15.4%10.5%5.8%10.5%
FCF/Rev LTM5.9%7.2%10.0%5.6%4.0%5.9%
FCF/Rev 3Y Avg5.6%8.1%8.4%4.9%4.9%5.6%

Valuation

SGRYTHCHCAUHSUNHMedian
NameSurgery .Tenet He.HCA Heal.Universa.UnitedHe. 
Mkt Cap2.017.4113.414.3296.817.4
P/S0.60.81.60.80.70.8
P/EBIT4.94.810.47.211.37.2
P/E-11.612.819.010.416.912.8
P/CFO7.07.09.57.314.27.3
Total Yield-8.6%7.8%5.9%10.0%8.6%7.8%
Dividend Yield0.0%0.0%0.6%0.4%2.6%0.4%
FCF Yield 3Y Avg5.0%13.5%6.4%6.1%4.5%6.1%
D/E1.90.80.40.40.30.4
Net D/E1.80.60.40.30.20.4

Returns

SGRYTHCHCAUHSUNHMedian
NameSurgery .Tenet He.HCA Heal.Universa.UnitedHe. 
1M Rtn-7.5%-9.5%-8.0%-6.8%1.1%-7.5%
3M Rtn-27.6%0.5%14.4%15.0%-4.6%0.5%
6M Rtn-28.0%14.6%25.9%28.2%9.7%14.6%
12M Rtn-25.6%52.5%56.8%25.8%-33.7%25.8%
3Y Rtn-41.4%324.0%101.8%63.6%-34.9%63.6%
1M Excs Rtn-7.4%-11.2%-8.6%-7.5%-0.0%-7.5%
3M Excs Rtn-32.6%-4.4%9.5%10.0%-9.5%-4.4%
6M Excs Rtn-40.9%1.7%13.1%15.3%-3.2%1.7%
12M Excs Rtn-43.2%35.9%40.4%9.7%-49.8%9.7%
3Y Excs Rtn-120.2%271.8%21.9%-10.3%-115.5%-10.3%

Financials

Segment Financials

Assets by Segment
$ Mil20242023202220212020
Surgical Facilities6,3476,0015,5534,9624,580
All other493639517416351
Ancillary Services3642483570
Total6,8776,6826,1185,4135,001


Price Behavior

Price Behavior
Market Price$15.63 
Market Cap ($ Bil)2.0 
First Trading Date10/01/2015 
Distance from 52W High-39.6% 
   50 Days200 Days
DMA Price$18.16$21.29
DMA Trenddowndown
Distance from DMA-13.9%-26.6%
 3M1YR
Volatility60.7%48.5%
Downside Capture41.9279.03
Upside Capture-118.0537.85
Correlation (SPY)-1.9%27.7%
SGRY Betas & Captures as of 11/30/2025

 1M2M3M6M1Y3Y
Beta-0.96-0.040.030.860.761.15
Up Beta-6.19-2.86-2.180.320.610.99
Down Beta1.791.861.651.800.920.83
Up Capture-212%-93%-77%2%40%157%
Bmk +ve Days13263974142427
Stock +ve Days9223061114346
Down Capture100%52%52%123%99%109%
Bmk -ve Days7162452107323
Stock -ve Days11193263131400

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
 Comparison of SGRY With Other Asset Classes (Last 1Y)
 SGRYSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return-20.3%16.4%19.2%71.9%8.9%6.0%-10.1%
Annualized Volatility48.9%17.3%19.5%19.3%15.3%17.1%35.0%
Sharpe Ratio-0.300.720.782.690.360.18-0.12
Correlation With Other Assets 26.9%28.3%-5.7%-5.4%27.3%6.1%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
 Comparison of SGRY With Other Asset Classes (Last 5Y)
 SGRYSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return-10.3%8.6%14.9%18.7%11.7%4.8%32.7%
Annualized Volatility56.1%14.5%17.1%15.5%18.7%18.9%48.7%
Sharpe Ratio0.030.410.700.970.510.170.60
Correlation With Other Assets 39.4%46.9%7.4%9.8%46.1%22.3%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
 Comparison of SGRY With Other Asset Classes (Last 10Y)
 SGRYSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return-2.8%9.8%14.7%14.9%6.9%5.2%69.3%
Annualized Volatility65.4%16.6%18.0%14.8%17.6%20.8%55.8%
Sharpe Ratio0.240.480.700.830.310.220.90
Correlation With Other Assets 39.6%44.7%0.8%16.2%43.2%11.8%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date12152025
Short Interest: Shares Quantity14,484,597
Short Interest: % Change Since 113020252.0%
Average Daily Volume2,074,718
Days-to-Cover Short Interest6.98
Basic Shares Quantity127,206,000
Short % of Basic Shares11.4%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/10/2025-25.4%-28.9%-23.1%
8/5/2025-0.3%2.4%1.3%
5/12/20255.0%8.0%5.2%
3/3/2025-0.3%-0.1%-1.4%
11/12/2024-5.9%-30.5%-33.2%
8/6/20243.2%1.3%7.7%
5/7/20248.5%1.1%3.2%
2/26/2024-8.6%-5.6%-13.5%
...
SUMMARY STATS   
# Positive91011
# Negative11109
Median Positive4.3%7.0%7.7%
Median Negative-5.9%-4.7%-13.5%
Max Positive17.0%27.4%32.5%
Max Negative-25.4%-42.0%-65.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
93020251110202510-Q 9/30/2025
6302025805202510-Q 6/30/2025
3312025512202510-Q 3/31/2025
12312024307202510-K 12/31/2024
93020241112202410-Q 9/30/2024
6302024806202410-Q 6/30/2024
3312024507202410-Q 3/31/2024
12312023226202410-K 12/31/2023
93020231107202310-Q 9/30/2023
6302023801202310-Q 6/30/2023
3312023502202310-Q 3/31/2023
12312022301202310-K 12/31/2022
93020221108202210-Q 9/30/2022
6302022802202210-Q 6/30/2022
3312022503202210-Q 3/31/2022
12312021301202210-K 12/31/2021

Insider Activity

Expand for More
 OwnerTitleFiling DateActionPriceSharesTransacted
Value
Value of
Held Shares
Form
0DeLuca Teresa 8152025Sell22.7420,018455,2091,027,234Form
1Maryland Patricia Anne 8132025Sell22.7420,018455,209103,808Form
2Doherty David TChief Financial Officer8082025Sell23.3947,4911,110,8142,417,988Form
3Baldock JenniferChief Admin & Dev Officer3172025Sell23.9461214,6515,650,965Form
4Burkhalter DanielleChief Human Resources Officer3172025Sell23.78741,7601,066,271Form